Long-Acting Injectables
TB Alliance is advancing long-acting injectable (LAI) formulations as part of its strategy to further shorten and simplify tuberculosis (TB) treatment. While oral regimens have enabled major progress, treatment duration and adherence remain key barriers to achieving optimal outcomes at scale. LAIs offer a complementary approach with the potential to extend drug exposure over weeks to months from a single administration, thereby reducing dosing frequency and enabling treatment durations beyond what is feasible with conventional oral delivery.
This approach is central to TB Alliance’s 1×1 vision—one-month treatment for active TB and one-day treatment for latent TB infection. For latent TB, LAIs could enable a “test-and-treat” model in which diagnosis and treatment occur in a single visit. For active TB, LAIs may be used following a short oral lead-in phase, maintaining therapeutic drug levels and reducing the overall treatment burden.
TB Alliance is currently evaluating LAI formulations of several key compounds within its portfolio, including pretomanid, sorfequiline, TBAJ-587, and Q-203. Preclinical studies have demonstrated promising pharmacokinetic profiles for multiple candidates, including sustained systemic exposure over extended periods following a single administration.
Development efforts prioritize formulations that are scalable, affordable, and suitable for use in high-burden settings, with consideration given to manufacturability, regulatory pathways, and delivery by local healthcare providers. Together, these efforts aim to integrate novel drug regimens with innovative delivery technologies to achieve transformative reductions in TB treatment duration and complexity.